A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.

NCT Number	NCT07161414
Lead Sponsor	AstraZeneca Collaborators: Parexel
Conditions	Advanced Solid Tumors
Enrollment	40 participants
Start Date	2025-11-25
Primary Completion	2027-07-19 (estimated)
Study Completion	2029-07-24 (estimated)
Updated on ClinicalTrials.gov	2026-08-10